Observational Study
Copyright ©The Author(s) 2023.
World J Clin Cases. May 16, 2023; 11(14): 3224-3237
Published online May 16, 2023. doi: 10.12998/wjcc.v11.i14.3224
Table 2 Incidence rate of intestinal complications (combined and segregated by type of intestinal complications) in general population with Crohn’s disease (n = 16809), patients with no evidence of anti-tumor necrosis factor therapy (conventional therapy-only, n = 12163), and patients with evidence of anti-tumor necrosis factor therapy (n = 4646)

Total number of events
First event1 (n)
PY
IR per 100 PY (95%CI)
General patients with CD (n = 16809)
Overall (combined)14697463361931.847.48 (7.27–7.68)
Associated disease9429416263123.616.59 (6.39–6.78)
Procedure-related4707270667528.544.00 (3.85–4.15)
CD hospitalization-related56145473645.510.61 (0.55–0.67)
CVT-only (n = 12163)
Overall6415302644431.396.8105 (6.5763–7.0447)
Associated disease5890273945060.276.0785 (5.8579–6.2991)
Procedure-related2934176847820.303.6972 (3.5281–3.8663)
CD-related hospitalization28624751654.410.5782 (0.4187–0.5377)
Evidence of anti-TNF therapy (4646)
Overall3928160717500.459.1826 (8.7548–9.6105)
Associated disease3539142318063.347.8778 (7.485–8.2707)
Procedure-related177393819708.244.7594 (4.4622–5.0567)
CD hospitalization-related27520721991.10.9413 (0.8137–1.0689)